|1.||Mürtz, Gerd: 6 articles (08/2012 - 09/2005)|
|2.||Strugala, Gerhard: 5 articles (08/2012 - 03/2009)|
|3.||Sugaya, Kimio: 4 articles (10/2014 - 10/2006)|
|4.||Nishijima, Saori: 4 articles (10/2014 - 10/2006)|
|5.||Yamaguchi, Osamu: 4 articles (06/2014 - 09/2007)|
|6.||Yokoyama, Osamu: 4 articles (04/2014 - 04/2011)|
|7.||Gotoh, Momokazu: 4 articles (10/2011 - 09/2007)|
|8.||Uchida, Shinya: 3 articles (01/2015 - 06/2007)|
|9.||Ashitomi, Katsuhiro: 3 articles (10/2014 - 09/2011)|
|10.||Kadekawa, Katsumi: 3 articles (10/2014 - 09/2011)|
|1.||Overactive Urinary Bladder (Overactive Bladder)
03/01/2008 - "The present study was prospectively conducted for female patients with wet overactive bladder to assess the efficacy of propiverine hydrochloride in improving their symptoms and quality of life (QOL). "
01/01/2006 - "This study aims to compare the efficacy of propiverine hydrochloride immediate release (IR), propiverine hydrochloride extended release (ER) and placebo for the treatment of overactive bladder syndrome. "
06/01/2010 - "To investigate the effects of a daily regimen of propiverine 20 mg in patients with an overactive bladder (OAB), focused on improving urgency, as the clinical efficacy of treatment for OAB should be measured in terms of urgency, the cornerstone symptom of OAB. "
07/01/2013 - "Terazosine and placebo were administered to the patients in Group 1 and terazosine plus propiverine HCL was administered to Group 2. The patients were evaluated by international prostate symptom score (IPSS), the first four questions of IPSS (IPSS4), the 8th question of IPSS (quality of life-QoL), overactive bladder symptom score questionnaire (OAB-q V8), PSA test, urodynamic studies, post voiding residue (PVR). "
05/01/2011 - "Editorial comment from Dr Sekido to propiverine hydrochloride in Japanese patients with overactive bladder: a randomized, double-blind, placebo-controlled trial."
|2.||Urge Urinary Incontinence (Urge Incontinence)
03/01/2003 - "These findings were confirmed by the overall assessment after four weeks in which approximately 90 % of patients under propiverine were either free from urge incontinence and urge symptoms or improved. "
06/01/2000 - "These findings were confirmed by the overall assessment at V4, in which approximately 90% of patients under propiverine either had no urge incontinence or urge symptoms, or showed improvement. "
01/01/1998 - "These results suggest that propiverine hydrochloride is a safe and effective drug of choice for the treatment of not only urge incontinence but also stress incontinence in patients diagnosed in a clinical setting."
09/01/1995 - "The results suggest that propiverine is a safe and effective drug for the treatment of urgency and urge incontinence. "
03/01/2003 - "The efficacy of propiverine in elderly patients suffering from urge incontinence or urge-stress incontinence was intended to be investigated. "
03/01/2009 - "This clinical trial showed superior efficacy of propiverine over placebo and good tolerability for the treatment of children suffering from OAB and urinary incontinence. "
09/01/1998 - "These results provide further evidence of the safety and efficacy of propiverine hydrochloride (BUP-4 tablets) even when administered for a long-term in the treatment of patients with pollakiuria and urinary incontinence."
09/01/1998 - "[Long-term administration study of propiverine hydrochloride (BUP-4 tablets) in pollakiuria and urinary incontinence]."
03/01/1998 - "Propiverine hydrochloride was given to patients with subjective symptoms of urinary incontinence and its effect was evaluated in relation to the pathogenesis of incontinence. "
03/01/1998 - "[Clinical effect of propiverine hydrochloride on urinary incontinence]."
02/01/2011 - "Significant improvement was observed with additional propiverine in the frequency of nocturia on voiding diary, total IPSS, voiding symptom, storage symptom and nocturnal voiding scores. "
09/01/2007 - "All active treatments vs placebo improved the volume voided (P < 0.001 for all) and QoL; solifenacin 10 mg reduced nocturia episodes (P = 0.021) and significantly improved urgency episodes (P = 0.012) and volume voided (P = 0.009) vs propiverine 20 mg, and solifenacin 5 mg caused less dry mouth (P = 0.003). "
02/01/2011 - "In conclusion, the results indicate that additional administration of propiverine may be useful for the patients with BPH who have naftopidil-resistant nocturia. "
02/01/2011 - "The efficacy and safety of additional administration of propiverine were prospectively studied for naftopidil-resistant nocturia in patients with benign prostatic hypertrophy (BPH). "
02/01/2011 - "[Additional effect of propiverine for naftopidil-resistant nocturia in the patient with benign prostate hypertrophy]."
|5.||Abnormal Reflex (Hyperreflexia)
03/01/1999 - "Propiverine proved its efficacy in detrusor hyperreflexia with regard to the urodynamic parameters of the maximal cystometric bladder capacity and detrusor contractility. "
03/01/1999 - "Efficacy and safety of propiverine in SCI-patients suffering from detrusor hyperreflexia--a double-blind, placebo-controlled clinical trial."
03/01/1999 - "The aim of this double-blind, randomised, prospective, multicentre trial was to evaluate the efficacy of propiverine in patients suffering from detrusor hyperreflexia caused by spinal cord injury in comparison to placebo. "
10/01/1997 - "The positive risk-benefit relationship of propiverine hydrochloride in the treatment of detrusor hyperactivity, hypersensitivity and hyperreflexia was reconfirmed in this post-marketing drug surveillance study."
10/01/1997 - "Clinical efficacy of propiverine hydrochloride was verified by the improvement of symptoms related to detrusor hyperactivity, hypersensitivity and hyperreflexia during a 12-week surveillance period: daytime and overnight urinary incontinence, as well as the frequency, nocturia, urgency in day time and at night decreased. "
|2.||quinuclidin- 3'- yl- 1- phenyl- 1,2,3,4- tetrahydroisoquinoline- 2- carboxylate monosuccinate (solifenacin)
|6.||Cholinergic Antagonists (Anticholinergics)
|10.||Cholinergic Agents (Cholinergics)
|3.||Kampo Medicine (Kampo)